Mewery Appoints Believer Meats’ Dr. Moria Shimoni as CTO & Hits 300 g/L Yield

Brno, Czech Republic – March 2026 – Mewery, a biotech company advancing next-generation protein production. They combine microalgae and mammalian cells in controlled bioreactors to build a scalable protein platform. The company has welcomed Dr. Moria Shimoni as Chief Technology Officer, achieved a significant breakthrough in scalable bioprocess performance, expanded its investor base with deep-tech venture fund Vesna Capital, and is currently raising additional funding to support its next stage of growth.

Dr. Moria Shimoni Joins as CTO

Mewery has appointed Dr. Moria Shimoni as Chief Technology Officer, bringing extensive experience in scaling cultivated meat technologies from her previous roles as CTO at Believer Meats (Future Meat Technologies) and Forsea Foods.

During her career, Shimoni has contributed to the development of industrial cultivated meat production systems, including the design of one of the world’s largest cultivated meat facilities, the development of multi-species platforms, and the advancement of technologies toward pre-commercial production and regulatory approval.

Her appointment strengthens Mewery’s ability to move its technology from pre-pilot development toward industrial implementation.

“The cultivated meat sector is entering a phase where technological robustness and industrial experience become critical,” said Roman Lauš, Founder and CEO of Mewery. “Moria brings exactly the kind of expertise needed to translate promising research into scalable production processes.”

“When I first saw Mewery’s co-cultivation concept, I instantly thought it was a real chance to overcome the toughest hurdles in the industry: efficiency, unit economics, and ultimately profitability,” said Dr. Moria Shimoni, CTO of Mewery.

Breakthrough in Scalable Cultivation

Mewery has recently achieved a key milestone in its bioprocess development by mastering stable suspension cultivation of porcine cells, enabling a simplified and scalable production process without the need for scaffolding.

The company has also implemented a continuous growth and harvesting strategy, significantly increasing biomass productivity.

As part of this progress, Mewery reports achieving a biomass yield of 300 g/L, placing it among the highest-yielding approaches reported in the cellular agriculture sector. Higher biomass density increases productivity per cultivator and significantly strengthens the unit economics for cultivated meat production.

“Yield is one of the fundamental parameters determining whether cultivated meat can become commercially viable,” added Roman Lauš. “Achieving this level of biomass density confirms that our technology can deliver the performance needed for industrial-scale production.”

New Investor and Ongoing Funding Round

Alongside its technological progress, Mewery strengthened its position last year with the entry of the Croatian deep-tech fund Vesna Capital. This investor, which specializes in disruptive innovations with a high social impact, chose Mewery for its unique technological solution with the potential to transform the global food industry. For Mewery, this was a pivotal decision due to the fund’s strong international track record and its focus on groundbreaking innovations that will help the startup translate its research into industrial practice. The investment thus confirms growing confidence in the company’s long-term vision and its ability to succeed with scientific research on a global scale.

At the same time, Mewery is currently raising additional funding to support the next stage of development, including industrial validation of its technology, pilot-scale production with several partners in Europe, and regulatory preparations as the company moves closer to future commercialization.

About Mewery

Mewery is a leading food and deep-tech startup developing a platform for cell-cultivated meat products using a proprietary method of co-culturing animal and microalgae cells. Their globally unique method leverages the advantages of both organisms, reducing mammalian cell death and increasing overall yield, fortifying the mass with richer nutrients, and cultivating them in food-grade bioreactors at low CAPEX. Mewery is currently working to scale up its method to semi-industrial volumes through strategic partnerships and ongoing innovation.